From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

As Bidstack shares continue to tank CEO Lyin’ James Draper takes to LinkedIn for an unofficial trading statement

By Tom Winnifrith, The Sheriff of AIM | Wednesday 6 November 2019


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Of course what Bidstack (BIDS) should be doing is issuing a trading statement via RNS. Does it still expect to have 24 games live by December 31 as forecast by Peterhouse. Or to have FY revenues of £5.75 million (having managed £26,000 in H1) or to achieve FY losses of just £500,000 (having lost £1.5 million in H1). The answer of course is No, No and No which is why the company should be issuing a formal profits warning and if Nomad Mark Brady at SPARK was not such an utter poltroon he’d be forcing the issue. Instead Lyin’ James Draper has issued a trading statement on LinkedIn. My guess is that his nose is just that bit longer as a result.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 10:12:12